HLB said Friday that the first global clinical phase 3 results of its liver cancer drug, rivoceranib, and camrelizumab, will be presented orally at the proffered paper session of the European Society for Medical Oncology (ESMO) on Sept. 10.
 

Please refer to the following website for further details:  

http://www.koreabiomed.com/news/articleView.html?idxno=14428